首页/数据集/Prognostic value of tumour-based E-cad, β-cat, Fascin, Snail, Zeb-1 and stromal PN in CRC samples.

Prognostic value of tumour-based E-cad, β-cat, Fascin, Snail, Zeb-1 and stromal PN in CRC samples.

Figshare2024-06-27 更新2026-04-28 收录

数据链接：

https://figshare.com/articles/dataset/Prognostic_value_of_tumour-based_E-cad_-cat_Fascin_Snail_Zeb-1_and_stromal_PN_in_CRC_samples_/26120167 数据链接链接失效反馈

官方服务：

资源简介：

Prognostic value of tumour-based E-cad, β-cat, Fascin, Snail, Zeb-1 and stromal PN in CRC samples.

应用场景：

创建时间：

2024-06-27

结直肠癌复发

肿瘤生物标志物

One of the main aims of the follow-up after curative resection of colorectal cancer is the early detection and treatment of tumor recurrence. We previously demonstrated decreased preoperative soluble

Figshare2016-01-15 更新50

Associations between HLA-G 3’UTR haplotypes with disease free survival and overall survival in 253 stage II-III CRC patients (N = 506).

结直肠癌预后

HLA-G单倍型分析

Associations between HLA-G 3’UTR haplotypes with disease free survival and overall survival in 253 stage II-III CRC patients (N = 506).

Figshare2016-02-23 更新20

Phase Fase II examination of irinotecan, cetuximab and everolimus for patients resistente to chemoptherapy with metastatic colorectal cancer and KRAS mutation or with KRAS wildtype after progression on therapy with irinotecan og cetuximab – effect and biological markers.

结直肠癌靶向治疗

肿瘤生物标志物

Main objective: • Disease control as the sum of number of patients with CR, PR and SD. Primary endpoints: Disease control as sum of number of patients with CR, PR, and SD

NIAID Data Ecosystem20

Artificial neural network identified a 20-gene panel with promising value in predicting immunotherapy response and survival benefits after anti-PD1/PD-L1 treatment in GBM patients

GBM胶质母细胞瘤

肿瘤生物标志物

Question: Which biomarker can effectively predict the immunotherapy response and prognostic benefits of GBM patients, and how can potential responders to immune checkpoint inhibitors (ICIs) be disc

Figshare2021-02-25 更新40

BRCAness, SLFN11 and RB1 loss predict response to topoisomerase I inhibitors in triple negative breast cancers. BRCAness, SLFN11 and RB1 loss predict response to topoisomerase I inhibitors in triple negative breast cancers

乳腺癌药物反应

肿瘤生物标志物

Expression data from patient-derived xenografts of human triple-negative breast cancers Overall design: We used GeneChip Human 1.1 ST arrays to identify the genes differentially expressed in PDX with

NIAID Data Ecosystem20

Prognostic value of tumour-based E-cad, β-cat, Fascin, Snail, Zeb-1 and stromal PN in CRC samples.

资源简介：

相关数据集